rnational Application No

r CT/GB2004/005343

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K16/22 461P A61P25/28 C12N05/08 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7K C12N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO 03/088926 A (PHARMACIA & UPJOHN 1 - 6COMPANY; YAN, RIQIANG; LU, YIFENG) 30 October 2003 (2003-10-30) cited in the application page 4, line 5 - page 5, line 8 page 17, lines 15-18 claims 43-45 X WO 02/058323 A (GLAXO GROUP LIMITED; 1-6 SMITHKLINE BEECHAM PLC; BLACKSTOCK, WALTER, PHILI) 25 July 2002 (2002-07-25) cited in the application page 2, lines 8-27 page 14, lines 14-26 page 15, lines 28-31 page 16, lines 6-18 examples 5.6 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the internation. "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-ments, such combination being obvious to a person skilled in the art. citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 3 June 2005 10/06/2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Noë, V

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

rnational Application No

		rC1/GB2004/005343		
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 00/31235 A (SCHWAB, MARTIN, E; CHEN, MAIO, S) 2 June 2000 (2000-06-02) page 4, lines 12-21 page 11, lines 3,4 page 11, line 33 page 28, line 1 - page 29, line 32 page 42, line 20 - page 43, line 25 page 59, lines 1-10	7,10, 12-14, 18,19		
X	STRITTMATTER S M: "MODULATION OF AXONAL REGENERATION IN NEURODEGENERATIVE DISEASE FOCUS ON NOGO" JOURNAL OF MOLECULAR NEUROSCIENCE, BIRKHAEUSER, CAMBRIDGE, MA, US, vol. 19, no. 1/2, August 2002 (2002-08), pages 117-121, XP009029170 ISSN: 0895-8696 the whole document	7,10-13, 19		
Α	US 2003/113891 A1 (BLATT LAWRENCE ET AL) 19 June 2003 (2003-06-19) the whole document			
P,X	WO 2004/052932 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; UNIVERSITAET ZUERICH; BARSKE, CARME) 24 June 2004 (2004-06-24) abstract page 18, last paragraph examples 3,4	7,10, 12-14, 18,19		
P,X	WO 2004/093893 A (STRITTMATTER, STEPHEN, M; LEE, DANIEL, H., S; LI, WEIWEI) 4 November 2004 (2004-11-04) cited in the application paragraphs '0004!, '0005!, '0010!, '0014!, '0021!, '0029!, '0069!, '0070!	1-19		
E	WO 2005/028508 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; UNIVERSITY OF ZURICH; BARSKE, CARME) 31 March 2005 (2005-03-31) abstract page 2, last paragraph page 20, last paragraph	7-13,18, 19		

International application No. PCT/GB2004/005343

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)							
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:							
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:							
Although claims 1-6 (insofar directed to in vivo methods) and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.							
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:							
see FURTHER INFORMATION sheet PCT/ISA/210							
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).							
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)							
This International Searching Authority found multiple inventions in this International application, as follows:							
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.							
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.							
As only some of the required additional search feet were three and but to a visit by the search sear							
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:							
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:							
The state of the s							
Romarti an Dratest							
Remark on Protest The additional search fees were accompanied by the applicant's protest.							
No protest accompanied the payment of additional search fees.							

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 1-6 (insofar directed to in vivo methods) and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Present claims 1-5,7-12 relate to a methods and uses of a product defined by reference to a desirable characteristic or property, namely a Nogo antagonist. The claims cover methods and uses of all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to methods or uses of function blocking monoclonal NogoA antibodies (see examples).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

mational Application No PCT/GB2004/005343

				FC1/GB2	004/005343
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03088926	A .	30-10-2003	AU CA WO US	2003223330 A1 2482589 A1 03088926 A2 2004063161 A1	03-11-2003 30-10-2003 30-10-2003 01-04-2004
WO 02058323	Α	25-07-2002	EP WO JP US	1352084 A2 02058323 A2 2004531697 T 2004146953 A1	15-10-2003 25-07-2002 14-10-2004 29-07-2004
WO: 0031235		02-06-2000	AU AU BR CA CN CZ EP HU JP MX NO NZ PL SK WO ZA	774367 B2 1469200 A 9915137 A 2350395 A1 1354755 A 20011608 A3 1124846 A2 0301829 A2 2003531566 T PA01004598 A 20012223 A 511683 A 362990 A1 6222001 A3 0031235 A2 200103714 A	24-06-2004 13-06-2000 08-06-2004 02-06-2000 19-06-2002 17-10-2001 22-08-2001 28-08-2003 28-10-2003 24-04-2002 02-07-2001 25-06-2004 15-11-2004 03-12-2001 02-06-2000 25-06-2004
US 2003113891	A1	19-06-2003	US EP WO US AU CA EP JP WO	2003060611 A1 1386004 A2 02081628 A2 2003203870 A1 3811101 A 2398282 A1 1265995 A2 2003525037 T 0159103 A2	27-03-2003 04-02-2004 17-10-2002 30-10-2003 20-08-2001 16-08-2001 18-12-2002 26-08-2003 16-08-2001
WO 2004052932	A	24-06-2004	AU WO	2003289998 A1 2004052932 A2	30-06-2004 24-06-2004
WO 2004093893	Α	04-11-2004	WO	2004093893 A2	04-11-2004
WO 2005028508	Α	31-03-2005	WO	2005028508 A2	31-03-2005